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Abstract
Background: Complementary and alternative medicine (CAM) therapies are used more than conventional therapies by people with
self-defined anxiety and depression. Preliminary evidence supports a hypothesis that low plasma concentration of essential fatty
acids is associated with depression. Reported here is the result of a systematic review examining the therapeutic efficacy of
essential fatty acids for depression.
Methods: Data sources included Medline, Psychinfo, AMED (Allied and Complementary Medicine), and Cochrane Controlled
Trials Register databases searched from inception through September 2001. English language randomized controlled trials,
controlled clinical trials, intervention studies, case control studies, reviews, and case reports of humans were selected, without
limits for demographics or co-morbidities. Two abstractors independently evaluated each study, then reconciled findings. When
possible, between group treatment effect size was noted or calculated.
Results: Six articles met inclusion criteria: one RCT, two reviews, and three case control trials. A common outcome measure
among the case control trials allowed for direct comparison of effect sizes.
Conclusions: The evidence implies promise of a treatment effect of omega-3 fatty acids for depression in adults; although a
statement of definitive clinical efficacy is premature. Further study of essential fatty acids as independent and adjuvant therapy for
adult depression is indicated, including more sophisticated investigation of dose-response in particular populations.
© 2006 Elsevier B.V. All rights reserved.
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1. Introduction
Depression is among the 10 most frequent indications
for using complementary and alternative medicine
(CAM) therapies (Kessler et al., 2001). A variety of
CAM modalities, including dietary supplements, is used
for the treatment of depression, although the quality and
quantity of evidence supporting them is quite variable
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doi:10.1016/j.jad.2006.02.023(Ernst et al., 1998). Among the more commonly used
supplements are omega-3 and omega-6 polyunsaturated
fatty acids (PUFAs) (Smit et al., 2004).
The literature suggests both a potential benefit of
essential fatty acid supplementation in affective dis-
orders, as well as likely mechanisms of action. Nations
which consume greater quantities of fish, high in
essential fatty acids (EFAs), experience lower rates of
major depression (Hibbeln, 1998). Furthermore, higher
concentrations of docosahexaenoic acid (DHA) in red
blood cell membranes (Edwards et al., 1998) and higher
eicosapentaenoic acid (EPA) to arachadonic acid (AA)
ratios in plasma (Adams et al., 1996) have been
associated with less severe levels of depression.
One polyunsaturated fatty acid, DHA, is selectively
concentrated in the brain (Carlson, 2001; Innis, 2000).
Furthermore, plasma concentrations of DHA predict low
concentrations of a marker of brain serotonin turnover,
cerebrospinal fluid 5-hydroxyindolacetic acid (CSF 5-
HIAA) (Hibbeln et al., 1997), strongly associated with
risk of depression and suicide (Hibbeln et al., 1998a), as
well as violence and early-onset alcoholism (Hibbeln et
al.,1998b).Despitethisliterature,definitiveevidenceofa
treatment effect of EFAs in depression is not established.
We therefore conducted a systematic review examining
the therapeutic efficacy of EFAs for depression.
2. Methods
With funding from the Centers for Disease Control
and Prevention, the Yale Prevention Research Center
initiated a systematic review of the evidence underlying
CAM in 2000. Using methods described elsewhere
(Katz et al., 2003; Williams et al., 2005), medical
conditions were paired with CAM interventions and,
when evidence existed, were prioritized for systematic
review. Depression and EFAs were a high priority pair.
2.1. Searching
The literature was searched electronically using
Medline, Psychinfo, AMED (Allied and Complemen-
tary Medicine), and the Cochrane Controlled Trials
Register. Only electronic search engines that are widely
available and accessible were used to ensure results
would be relevant to a broad audience. The searches,
conducted from December 2000 to September 2001,
investigated each database from the earliest date
available to the present. Three terms were entered into
the search engines with booleans: depression, essential
fatty acids, and a study design term.
2.2. Selection
All randomized controlled trials (RCT), controlled
clinical trials (CCT), intervention studies, case control
studies, reviews, case reports and pilot projects that
examined the evidence behind essential fatty acid use in
depression among humans were selected. All study
populations were acceptable, regardless of demograph-
ics or co-morbidities. Papers in all languages were
retrieved; however, only those in English were abstract-
ed and assessed for trial quality.
2.3. Validity assessment and data abstraction
Using methods applied by the Centers for Disease
Control and Prevention (CDC)to theGuide to Community
PreventiveServices(CDC),andincorporatingcriteriafrom
The Cochrane Reviewers' Handbook 4.0, (The Cochrane
Table 1
Summary of essential fatty acid and depression literature through 9/2001
Author/year Population (N) Study
type
Outcome
measure
Duration
of study
Effect size Quality
assessment
Stoll et al.
(1999)
Adults with bipolar
disorder (30)
RCT Time for mood
symptoms to occur
30 days Significantly longer period of remission
than the placebo group (favorable)
Accept
Maes et al.
(1999)
Adult inpatients with major
depression (34 cases)
CCT RBC membrane
omega-3 PUFA
N/A 2.43 mg/dl higher omega-3 PUFA in plasma
of non-depressed subjects (favorable)
Accept
Edwards et al.
(1998)
Adults with major
depression (10 cases)
CCT RBC membrane
omega-3 PUFA
N/A 1.21 mg/dl higher omega-3 PUFA in plasma
of non-depressed subjects (favorable)
Accept
Peet et al.
(1998)
Adults with major
depression (15 cases)
CCT RBC membrane
omega-3 PUFA
N/A 3.605 mg/dl higher omega-3 PUFA in plasma
of non-depressed subjects (favorable)
Accept
Horrocks and
Yeo (1999)
N/A Review N/A N/A N/A N/A
Bruinsma and
Taren (2000)
N/A Review N/A N/A N/A N/A
N/A = non-applicable.
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on-line data abstraction form. The Principal Investigator
provided training to two masters-level research associates
who abstracted the accepted articles, using a standardized
process.Thetwoabstractorsindependentlyevaluatedeach
study, and then reconciled their findings. For quality
assessment purposes, studies were “accepted,”“ rejected,”
or“audited”basedonprecisecriteriaforidentifyingthreats
to internal and external validity.
All studies involving an intervention and designated
“accepted” were further analyzed to facilitate compar-
ison. Plots were generated of outcome effect based on a
common measure. Point estimates were surrounded by
95% confidence intervals when sufficient data existed to
generate confidence bounds. When confidence levels
were lacking, data points reflected P-values reported in
the papers and indicated whether or not the results
observed were statistically significant.
3. Results
3.1. Study characteristics
Six articles were found that assessed essential
(omega-3 and omega-6) fatty acids as an intervention
for depression. One of the articles is a randomized
controlled trial (RCT) (Stoll et al., 1999), two are
reviews (Bruinsma and Taren, 2000; Horrocks and Yeo,
1999), and three are case control trials (Edwards et al.,
1998; Maes et al., 1999; Peet et al., 1998)( Table 1).
The double-blind placebo controlled RCT by Stoll et
al. (1999) examined the effects of omega-3 fatty acid
Depression/EFA/n-3 PUFA
1
3
2
-4 -2 0 2 4
Effect Size (RBC Membrane N-3 PUFA)
Legend N Type  Measure  Duration  Contact 
hours 
Effect 
size 
Effect** SD  P-value
1  Peet et al. 1998  30  Cross-
sectional 
RBC 
membrane 
omega-3 
PUFA 
N/A  N/A  3.605  1  NR  P < 0.02 
between 
groups 
2  Edwards et al. 
1998 
24
sectional/cas
e-control 
RBC 
membrane 
omega-3 
PUFA 
N/A  N/A  1.2  1  NR  P < 0.02 
between 
groups 
3  Maes et al. 1999  48  Cross-
sectional/cas
e-control 
RBC 
membrane 
omega-3 
PUFA 
N/A  N/A  2.43  1  NR  P < .001 
between 
groups 
** Effect (1 = favorable,  0 = none, -1 = unfavorable) 
Author/year
Cross-
Fig. 1. Distribution of effect sizes for studies of EFAs for depression.
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mean age 41.4 SD 13.6, 64% women). Subjects in the
intervention group received 9.6 g of omega-3 fatty acids
inthe formofencapsulatedfishoil inadditiontostandard
pharmacological treatment. The primary outcome mea-
sure was duration of time to exit double-blind treatment
due to exacerbation of symptoms of bipolar disorder.
The review article by Bruinsma and Taren (2000)
discussestheeffects ofdifferentdietaryintakepatternson
fatty acid balance and biogenic amine metabolism, which
inturn,couldaffectmood.ThereviewarticlebyHorrocks
andYeo(1999)suggeststhatDHAisbeneficialforcentral
nervous system and neurobehavioral development, as
well as dementia, depression, and various degenerative
disorders, including arthritis, atherosclerosis, diabetes,
and heart disease.
The CCT by Maes et al. (1999) examined serum
phospholipid status in hospitalized major depressed
patients diagnosed by DSM-IIIR criteria (n=34, mean
age 52.2 SD 13.6, 47% women) and normothymic
controls (n=14, mean age 48.3 SD 15.2, 45% women).
Twenty-six of the 34 patients were taking antidepressant
drugsduringthestudy;thecontrolsweredrug-freeforone
monthprior tobloodsampling.Notreatmentwas givento
eithergroup. Outcome measuresincluded serum saturated
fatty acids, monounsaturated fatty acids (MUFAs), and
polyunsaturated fatty acids (PUFAs). The second CCT by
Edwards et al. (1998) compared 10 major depressed
patientsdiagnosedbyDSM-IVcriteria(meanage38.7SD
10.2, 80% women) with 14 controls (mean age 39.4 SD
10.9,86%women).Primaryoutcomeswereredbloodcell
membrane levels of omega-3 PUFAs. The third CCT by
Peet et al. (1998) examined red blood cell membrane
levels of omega-3 PUFAs in unipolar major depressed
patients (n=15, mean age 47.4, 47% women) and
normothymic medication-free controls (n=15, mean age
47.0, 47% women). The main outcome measure was red
blood cell (RBC) membrane levels of omega-3 PUFAs.
3.2. Quantitative data synthesis
A significant treatment effect was found in the RCT
by Stoll et al. (1999). The intervention group receiving
omega-3 fatty acid supplementation was found to have a
significantly longer period of remission than the placebo
group (P=.002).
The common outcome measure found among the
three case control trials (Table 1), RBC membrane
omega-3 PUFA, allowed for direct comparison of effect
sizes (Fig. 1). The three CCTs (Edwards et al., 1998;
Maes et al., 1999; Peet et al., 1998) all had comparably
small sample sizes, and assessed between group
differences. The three CCTs also used similar case
populations (adults with major depression) and controls
(non-depressed, healthy adults). Favorable and signifi-
cant between group effect was seen in all three CCTs.
After the data abstraction and reconciliation phases,
none of the studies were rejected for major design flaws
that compromised internal or external validity. The three
case control trials all had minor flaws in descriptions of
the study populations; they were ultimately accepted.
4. Discussion
At the time of the systematic literature review
(concluding 9/01), there were no intervention studies
published describing treatment effects of EFAs for
unipolar depression, although the RCT by Stoll et al.
(1999) demonstrated significant benefit with bipolar
disorder. The review articles highlight the physiologic
rationale, further confirmed by the case control trials
demonstrating a definitive difference in omega-3 PUFAs
Table 2
Summary of essential fatty acid and depression clinical trials from 9/2001 to present
Author/year Population (N) Study type Outcome measure Duration of study
Peet and Horrobin (2002) Adults with persistent depression
on antidepressant therapy (70)
RCT MADRS and the HAM-D 12 weeks
Nemets et al.
(2002)
Adults with major depression on
antidepressant therapy (20)
RCT HAM-D 4 weeks
Su et al. (2003) Adults with major
depression (28)
RCT HAM-D 8 weeks
Marangell et al.
(2003)
Adults with major
depression (36)
RCT 50% reduction in the score
on the Montgomery–Asberg
Depression Rating Scale
6 weeks
Chiu et al. (2003) Pregnant woman with major depression (1) Case
report
HAM-D 10 weeks
Puri et al. (2002) Adult male with major
depression (1)
Case
report
MADRS 1 month
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finding was confirmed with a larger population in the
Rotterdam Study (Tiemeier et al., 2003).
A number of studies published after the completion of
the systematic review (Table 2) have further understand-
ing of the association between essential fatty acid intake
and depression. In 2002 and 2003, three randomized
controlled trials (Marangell et al., 2003; Peet and
Horrobin,2002;Suetal.,2003)wereconductedassessing
the value of omega-3 PUFAs in the treatment of major
depressive disorders. In a study of 36 depressed patients
randomly assigned to receive 2 g/day DHA or placebo,
Marangell et al. (2003) found no significant difference in
response rate as measured by the Montgomery–Asberg
Depression Rating Scale (MADRS), though the DHA
group had a better overall response rate. Su et al. (2003)
studied 28 patients with major depression, randomly
assigning them to receive omega-3 PUFAs 9.6 g/day or
placebo. Using the Hamilton Rating Scale for Depression
(HAM-D), the intervention group showed significant
improvement as compared to the placebo group. The
disparateresultsoftheMarangelletal.(2003)andSuetal.
(2003) studies may be attributable to the different
outcome measures used and/or the different dosing of
EFAs. A dose-ranging study of EPA (Peet and Horrobin,
2002) demonstrated significant improvement in both the
MADRS and the HAM-D for depressed adults receiving
1 g/day of EPA as compared to those receiving placebo
despite ongoing treatment with an adequate dose of a
standard antidepressant. No improvement was evident in
either depression scale for subjects receiving higher
dosages of EPA. This may imply a ceiling effect that can
correct relative dietary deficiencies.
In 2002, Nemets et al. (2002) studied the combina-
tion of EPA and conventional antidepressant treatment
on unipolar depressive disorder. In a 4-week study, 20
patients participated in a parallel-group, double-blind
addition of either EPA or placebo to ongoing antide-
pressant therapy. Significant treatment effects were seen
in the EPA group by the third week of treatment. This
result was consistent with a 2001 case report describing
a treatment-resistant, severely depressed and suicidal
male patient with a seven-year history of depression
who received adjuvant EPA therapy resulting in
significant clinical improvement of depressive symp-
toms and suicidal ideation after one month of treatment
(Puri et al., 2002). A 2003 case report of a pregnant
patient with major depressive disorder demonstrated
significant improvement in clinical symptoms as well
(Chiu et al., 2003).
Mamalakis et al. (2004) found an association between
depression and reduced levels of adipose tissue alpha-
linolenic levels in elderly males. In age- and sex-matched
pairs following an acute coronary syndrome episode,
Frasure-Smithetal.(2004)found lower concentrationsof
total serum omega-3 fatty acids and DHA as well as
higher AA:DHA, AA:EPA, and omega-6:omega-3 ratios
in depressed subjects when compared to controls. Assies
et al. (2004) found decreased levels of erythrocyte
omega-3 levels in a randomized sample of subjects with
recurrent major depressive disorders. Suzuki et al. (2004)
found that the prevalence of depression in newly
diagnosed lung cancer patients was lower in subjects
with the highest levels of total omega-3 fatty acid and
ALA intake, though no association was found between
EPA and DHA intake. McGrath-Hanna et al. (2003)
found an association between changing from a diet high
in omega-3 fatty acids to a westernized diet and increased
rates of depression, seasonal affective disorder, anxiety,
and suicide. Tiemeier et al. (2003) found slightly higher
ratios of serum omega-6 to omega-3 fatty acids in elderly
subjects with a depressive disorder. When controlling for
C-reactive protein concentration, a marker of systemic
inflammation, levels of omega-3 fatty acids as well as the
ratio of omega-3:omega-6 fatty acids were significantly
lower in subjects with depressive disorders. Furthermore,
risk of depression and suicide was found to be lower in
populations with high fish consumption, consistent with
other studies (Tanskanen et al., 2001). In a 2001
commentary (Magnusson et al., 2000) on the finding
that Icelandic populations exhibit lower incidences of
seasonal affective disorder, Cott and Hibbeln (2001)
suggest higher omega-3 fatty acid consumption among
Icelanders as an etiology.
In contrast, Jacka et al. (2004) found no differences
in omega-3 fatty acid intake in cohorts of depressed and
non-depressed women, although the total sample had
higher rates of depression than expected as well as lower
average omega-3 intakes.
A number of studies examined potential links
between essential fatty acid consumption and the
prevention of postpartum depression, although clinical
trails failed to demonstrate an effect (Hibbeln, 2002;
Otto et al., 2001). A cohort study of 380 women found a
1% plasma DHA increase was associated with a 59%
reduction of depression measured on the Edinburgh
Post-Partum Depression Scale (Makrides et al., 2003).
4.1. Mechanism of action
A number of probable mechanisms have been
described to explain the link between EFAs and
depression. These include modulation of serotonin
turnover, phosphoinositol-mediated signal transduction,
121 A. Williams et al. / Journal of Affective Disorders 93 (2006) 117–123and L-type calcium channel regulation (Cott and Hibbeln,
2001).Serotoninanddopaminemetabolismisaffectedby
DHA (Innis, 2000), as well as the ratio between omega-3
and omega-6 fatty acids (Haag, 2003). Animal studies
demonstrate higher frontal cortex dopamine levels and
lowermonoamineoxidaseB(MAO-B)activityintestrats
fed with omega-3 rich diets compared to omega-6 rich
diets (Chalon et al., 1998; Delion et al., 1996).
Other studies have reported the modification of 5-HT
receptors in the brain by EFAs (Yao et al., 2004) as well
as an association between plasma DHA levels and CSF
metabolites of serotonin (Hibbeln et al., 1998a). A high
positive correlation between Na/KATPase activity and
local concentrations of DHA was reported by Turner et
al. (2003), implicating the role of DHA in neurological
dysfunction, as nearly 60% of brain energy consumption
involves the Na/KATPase enzyme.
Embryologic evidence demonstrates the significance
of EFAs in normal brain development (Bourre, 2004;
Carlson, 2001; Innis, 2000). Deficiency has been shown
to alter sensory processes, including the perception of
pleasure,andsensitivityoftastereceptorstosweetstimuli
(Bourre, 2004) as well as to alter synaptic 5-HT levels
(Kodasetal.,2004).Furthermore,deficiencyisassociated
with lower phosphotidylserine levels, higher monoamine
oxidase-B levels (Delion et al., 1997), increased 5-HT2
receptor density in the frontal cortex during aging,
reduction dopaminergic D2 receptor density (Delion et
al., 1996), and possibly impaired neural signal transduc-
tion (Farooqu and Horrocks, 2001).
Anumberofotherpossiblemechanismsofactionhave
been proposed, including the modulation of cytokine
production(Mamalakisetal.,2004),inhibitionofsecond-
messengerrelatedproteinkinases(Mirnikjooetal.,2001),
as well as the inhibition of prostaglandin synthesis
affecting transport protein function (Murck et al., 2004).
5. Conclusion
Since cell membrane composition, neurotransmission
and prostaglandin formation is affected by amounts of
EFAs (Haag, 2003), it follows that these nutrients have
potential effects on psychology (Carlson, 2001; Su et al.,
2000)andphysiology(Bourre,2004).There issubstantial
evidence supporting the correlation betweenlow essential
fatty acid levels and depression, though clinical trials are
scant. As seen with research in other nutriceuticals
(Benton, 2002), it is possible that variability of results
across studies could be because EFA supplementation
works best for individuals within the study population
whoareloworfranklydeficientinEFAs.Whiledefinitive
evidence of a role for EFAs in the treatment of depression
is still lacking, this lack of evidence is not the same as
evidence oflack ofeffect.EFAs are vitalto overall health,
and western populations tend to be relatively deficient in
omega-3s(Hibbeln,1998).Thusanargumentcanbemade
for omega-3 supplementation as a health promotion
strategy, with potential to influence mental health and
mitigate depression. A specific role for these nutrients in
the treatment of affective disorders will require further
study attentive to dose, population characteristics, and
concurrent therapies.
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